Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Vasculitis Overview 8 Therapeutics Development 9 Pipeline Products for Vasculitis - Overview 9 Pipeline Products for Vasculitis - Comparative Analysis 10 Vasculitis - Therapeutics under Development by Companies 11 Vasculitis - Therapeutics under Investigation by Universities/Institutes 12 Vasculitis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Vasculitis - Products under Development by Companies 17 Vasculitis - Products under Investigation by Universities/Institutes 18 Vasculitis - Companies Involved in Therapeutics Development 19 AnGes MG, Inc. 19 ChemoCentryx, Inc. 20 Cipla Ltd. 21 Coherus BioSciences, Inc. 22 F. Hoffmann-La Roche Ltd. 23 GlaxoSmithKline Plc 24 Hemostemix Ltd 25 Johnson & Johnson 26 K-Stemcell Co., Ltd. 27 Panacea Biotec Limited 28 Pfizer Inc. 29 Sandoz International GmbH 30 Teijin Pharma Limited 31 Vasculitis - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 ACP-01 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 belimumab - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 beperminogene perplasmid - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 CCX-168 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 immune globulin (human) - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 PF-1355 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 rituximab biosimilar - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 rituximab biosimilar - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 rituximab biosimilar - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 sirukumab - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Stem Cell Therapy for Thromboangiitis - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Stempeucel - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 tocilizumab - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Vasculitis - Dormant Projects 84 Vasculitis - Product Development Milestones 86 Featured News & Press Releases 86 Jun 06, 2016: Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) 86 May 30, 2016: DCGI Gives Limited Approval to Market FIRST Allogeneic Cell Therapy Product in India Stempeutics puts India on the World map of Regenerative Medicine 86 Nov 25, 2015: GSK announces start of phase III study of sirukumab in Giant Cell Arteritis 87 Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans 88 Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel' 88 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 89 Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 90 Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 90 Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 90 May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 91 Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 92 Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 92 Appendix 93 Methodology 93 Coverage 93 Secondary Research 93 Primary Research 93 Expert Panel Validation 93 Contact Us 93 Disclaimer 94

List of Tables Number of Products under Development for Vasculitis, H2 2016 9 Number of Products under Development for Vasculitis - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Comparative Analysis by Unknown Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Vasculitis - Pipeline by AnGes MG, Inc., H2 2016 19 Vasculitis - Pipeline by ChemoCentryx, Inc., H2 2016 20 Vasculitis - Pipeline by Cipla Ltd., H2 2016 21 Vasculitis - Pipeline by Coherus BioSciences, Inc., H2 2016 22 Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 23 Vasculitis - Pipeline by GlaxoSmithKline Plc, H2 2016 24 Vasculitis - Pipeline by Hemostemix Ltd, H2 2016 25 Vasculitis - Pipeline by Johnson & Johnson, H2 2016 26 Vasculitis - Pipeline by K-Stemcell Co., Ltd., H2 2016 27 Vasculitis - Pipeline by Panacea Biotec Limited, H2 2016 28 Vasculitis - Pipeline by Pfizer Inc., H2 2016 29 Vasculitis - Pipeline by Sandoz International GmbH, H2 2016 30 Vasculitis - Pipeline by Teijin Pharma Limited, H2 2016 31 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Vasculitis - Dormant Projects, H2 2016 84 Vasculitis - Dormant Projects (Contd..1), H2 2016 85 List of Figures Number of Products under Development for Vasculitis, H2 2016 9 Number of Products under Development for Vasculitis - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 15 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Targets, H2 2016 33 Number of Products by Stage and Targets, H2 2016 33 Number of Products by Mechanism of Actions, H2 2016 35 Number of Products by Stage and Mechanism of Actions, H2 2016 35 Number of Products by Routes of Administration, H2 2016 37 Number of Products by Stage and Routes of Administration, H2 2016 37 Number of Products by Molecule Types, H2 2016 39 Number of Products by Stage and Molecule Types, H2 2016 39

AnGes MG, Inc. ChemoCentryx, Inc. Cipla Ltd. Coherus BioSciences, Inc. F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Hemostemix Ltd Johnson & Johnson K-Stemcell Co., Ltd. Panacea Biotec Limited Pfizer Inc. Sandoz International GmbH Teijin Pharma Limited